Autopsy report · NCT04190628
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Cause of deathFutility
“Not related to safety concerns or lack of efficacy”
Life of this trial
- Registered 6 months before it started.
- Ran for about 3 years 10 months before it stopped.
- 53 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- ABM Therapeutics Corporation
- Sponsor type
- Industry
- Conditions
- Advanced Solid Tumor; BRAF V600 Mutation
- Interventions
- ABM-1310; Cobimetinib
- Participants
- 53
- Sites
- 8
- Countries
- United States
Trials that died the same way
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
“Lack of Efficacy, no safety concern.” - A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
“This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” - Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
“Lack of efficacy of the drug; no safety concern” - A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
“Lack of efficacy” - Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
“Corporate reasons unrelated to safety and efficacy”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.